Literature DB >> 2843836

Distribution of bombesin binding sites in the rat gastrointestinal tract.

T H Moran1, T W Moody, A M Hostetler, P H Robinson, M Goldrich, P R McHugh.   

Abstract

In an attempt to identify potential target sites for the satiety action of bombesin (BN), the distribution and pharmacological specificity of bombesin binding sites were examined in the rat gastrointestinal tract by in vitro autoradiography utilizing (125I-Tyr4) bombesin. Specific BN binding was localized to the circular muscle level of the gastric fundus and antrum, submucosal layer of the small intestine and longitudinal and circular muscle and submucosal layers of the colon. Pharmacological studies indicated that gastrin releasing peptide (GRP), Ac-GRP20-27 and BN-like compounds, litorin and ranatensin, inhibited the binding of (125I-Tyr4)BN with high affinity while compounds which lacked COOH-terminal homology with BN demonstrated a low affinity for BN binding sites. The wide distribution of BN binding sites in the gastrointestinal tract provides a number of potential sites for the mediation of the satiety action of BN.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843836     DOI: 10.1016/0196-9781(88)90177-5

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

Review 1.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

2.  Gastrin-releasing peptide in human nasal mucosa.

Authors:  J N Baraniuk; J D Lundgren; J Goff; D Peden; M Merida; J Shelhamer; M Kaliner
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  Bombesin ameliorates colonic damage in experimental colitis.

Authors:  B M Güllüoğlu; H Kurtel; M G Güllüoğlu; A O Aktan; B C Yeğen; F Dizdaroğlu; R Yalin; B C Yeğen
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

4.  Distribution of vasoactive intestinal polypeptide and substance P receptors in human colon and small intestine.

Authors:  L Y Korman; H Sayadi; B Bass; T W Moody; J W Harmon
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

5.  Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Authors:  Maarten Brom; Wietske Woliner-van der Weg; Lieke Joosten; Cathelijne Frielink; Thomas Bouckenooghe; Paul Rijken; Karolina Andralojc; Burkhard J Göke; Marion de Jong; Decio L Eizirik; Martin Béhé; Tony Lahoutte; Wim J G Oyen; Cees J Tack; Marcel Janssen; Otto C Boerman; Martin Gotthardt
Journal:  Diabetologia       Date:  2014-02-01       Impact factor: 10.122

6.  Facilitation of the inhibitory transmission by gastrin-releasing peptide in the anterior cingulate cortex.

Authors:  XiaoYan Cao; Valentina Mercaldo; Pingyang Li; Long-Jun Wu; Min Zhuo
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

7.  Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis.

Authors:  W P ter Beek; E S M Muller; R A Van Hogezand; I Biemond; C B H W Lamers
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

8.  High-affinity binding sites for bombesin on mouse colonic mucosal membranes.

Authors:  S Narayan; E Draviam; S Rajaraman; P Singh
Journal:  Mol Cell Biochem       Date:  1991-07-24       Impact factor: 3.396

9.  Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.

Authors:  Y Qin; G Halmos; R Z Cai; B Szoke; T Ertl; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Bombesin improves survival from methotrexate-induced enterocolitis.

Authors:  K U Chu; S Higashide; B M Evers; S Rajaraman; J Ishizuka; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.